{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:22:36Z","timestamp":1769124156011,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Heart foundation of northern Sweden","award":["2017"],"award-info":[{"award-number":["2017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aims of this study were to examine sex differences in a heart failure population with regards to treatment and patient characteristics and to investigate the impact of sex on achieved doses of heart failure medications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results<\/jats:title>\n                <jats:p>A total of 1924 patients with heart failure in a regional hospital were analysed, 622 patients had ejection fraction \u2264 40% of which 30% were women. In patients with reduced ejection fraction, women were older (79 \u00b1 11 vs. 74 \u00b1 12 years, <jats:italic>P<\/jats:italic> &lt; 0.001), had lower body weight (70 \u00b1 17 vs. 86 \u00b1 18 kg, <jats:italic>P<\/jats:italic> &lt; 0.001), lower estimated glomerular filtration rate (eGFR) (49 \u00b1 24 vs. 71 \u00b1 30 ml\/min, <jats:italic>P<\/jats:italic> &lt; 0.001) and received lower doses of heart failure medications than men. Multivariable linear regression on patients with reduced ejection fraction showed that sex was not associated with achieved dose of any heart failure medication. For angiotensin-converting enzyme inhibitors and angiotensin receptor blockers associated factors were eGFR, systolic blood pressure, age, ejection fraction, and heart rate. For beta-blockers associated factors were body weight, atrial fibrillation and age. For mineralocorticoid receptor antagonists associated factors were eGFR, serum potassium, age, systolic blood pressure, ejection fraction and heart rate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Women with heart failure and reduced ejection fraction were prescribed lower doses of heart failure medications, were older, had worse renal function, and lower body weight than men. Sex was not independently associated with achieved doses of heart failure medications, instead age, renal function and body weight explained the differences in treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-019-02782-2","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T03:03:01Z","timestamp":1578020581000},"page":"539-546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Differences in medical treatment and clinical characteristics between men and women with heart failure \u2013 a single-centre multivariable analysis"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6785-2895","authenticated-orcid":false,"given":"Helena","family":"Norberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Pranic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellinor","family":"Bergdahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5756-7791","authenticated-orcid":false,"given":"Krister","family":"Lindmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"key":"2782_CR1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonz\u00e1lez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129\u20132200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"2782_CR2","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/cir.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey de Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride P, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC\/AHA\/HFSA Focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the heart failure society of America. Circulation 136:e137\u2013e161. https:\/\/doi.org\/10.1161\/cir.0000000000000509","journal-title":"Circulation"},{"key":"2782_CR3","doi-asserted-by":"crossref","unstructured":"(1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 353: 9-13","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"2782_CR4","doi-asserted-by":"publisher","unstructured":"(1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. the SOLVD investigators. N Engl J Med 325: 293\u2013302. https:\/\/doi.org\/10.1056\/NEJM199108013250501.","DOI":"10.1056\/NEJM199108013250501"},{"key":"2782_CR5","doi-asserted-by":"crossref","unstructured":"(1999) Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353: 2001\u20132007","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"2782_CR6","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets D, Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194\u20132199","journal-title":"Circulation"},{"key":"2782_CR7","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667\u20131675. https:\/\/doi.org\/10.1056\/NEJMoa010713","journal-title":"N Engl J Med"},{"key":"2782_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","volume":"362","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray J, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, CHARM Investigators and Committees (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362:759\u2013766","journal-title":"Lancet"},{"key":"2782_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/nejm199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709\u2013717. https:\/\/doi.org\/10.1056\/nejm199909023411001","journal-title":"N Engl J Med"},{"key":"2782_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen D, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"key":"2782_CR11","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"2782_CR12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/eurjhf\/hft064","volume":"15","author":"R Zarrinkoub","year":"2013","unstructured":"Zarrinkoub R, Wettermark B, Wandell P et al (2013) The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur J Heart Fail 15:995\u20131002. https:\/\/doi.org\/10.1093\/eurjhf\/hft064","journal-title":"Eur J Heart Fail"},{"key":"2782_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcmg.2017.08.007","volume":"11","author":"RS Vasan","year":"2018","unstructured":"Vasan RS, Xanthakis V, Lyass A, Andersson C, Tsao C, Cheng S, Aragam J, Benjamin EJ, Larson MG (2018) Epidemiology of left ventricular systolic dysfunction and heart failure in the Framingham study: an echocardiographic study over 3 decades. JACC Cardiovasc Imaging 11:1\u201311. https:\/\/doi.org\/10.1016\/j.jcmg.2017.08.007","journal-title":"JACC Cardiovasc Imaging"},{"key":"2782_CR14","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/eurheartj\/ehs070","volume":"33","author":"JE Ho","year":"2012","unstructured":"Ho JE, Gona P, Pencina MJ, Tu JV, Austin PC, Vasan RS, Kannel WB, D'Agostino RB, Lee DS, Levy D (2012) Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. Eur Heart J 33:1734\u20131741. https:\/\/doi.org\/10.1093\/eurheartj\/ehs070","journal-title":"Eur Heart J"},{"key":"2782_CR15","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.ejheart.2003.11.021","volume":"6","author":"C Opasich","year":"2004","unstructured":"Opasich C, De Feo S, Ambrosio GA et al (2004) The 'real' woman with heart failure. Impact of sex on current in-hospital management of heart failure by cardiologists and internists. Eur J Heart Fail 6:769\u2013779. https:\/\/doi.org\/10.1016\/j.ejheart.2003.11.021","journal-title":"Eur J Heart Fail"},{"key":"2782_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.amjcard.2009.02.057","volume":"104","author":"GC Fonarow","year":"2009","unstructured":"Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy C, Young JB, OPTIMIZE-HF Investigators and Hospitals (2009) Age- and gender-related differences in quality of care and outcomes of patients hospitalized with heart failure (from OPTIMIZE-HF). Am J Cardiol 104:107\u2013115. https:\/\/doi.org\/10.1016\/j.amjcard.2009.02.057","journal-title":"Am J Cardiol"},{"key":"2782_CR17","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","volume":"19","author":"O Chioncel","year":"2017","unstructured":"Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G (2017) Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19:1574\u20131585. https:\/\/doi.org\/10.1002\/ejhf.813","journal-title":"Eur J Heart Fail"},{"key":"2782_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ejhf.496","volume":"18","author":"T Thorvaldsen","year":"2016","unstructured":"Thorvaldsen T, Benson L, Dahlstrom U, Edner M, Lund LH (2016) Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012. Eur J Heart Fail 18:503\u2013511. https:\/\/doi.org\/10.1002\/ejhf.496","journal-title":"Eur J Heart Fail"},{"key":"2782_CR19","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.jacc.2018.02.070","volume":"71","author":"PE Scott","year":"2018","unstructured":"Scott PE, Unger EF, Jenkins MR, Southworth MR, McDowell T, Geller RJ, Elahi M, Temple RJ, Woodcock J (2018) Participation of women in clinical trials supporting FDA approval of cardiovascular drugs. J Am Coll Cardiol 71:1960\u20131969. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.070","journal-title":"J Am Coll Cardiol"},{"key":"2782_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jamacardio.2018.2559","volume":"3","author":"AS Tahhan","year":"2018","unstructured":"Tahhan AS, Vaduganathan M, Greene SJ, Fonarow GC, Fiuzat M, Jessup M, Lindenfeld J, O'Connor CM, Butler J (2018) Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review. JAMA Cardiol 3:1011\u20131019. https:\/\/doi.org\/10.1001\/jamacardio.2018.2559","journal-title":"JAMA Cardiol"},{"key":"2782_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/eurjhf\/hfn041","volume":"11","author":"M Baumhakel","year":"2009","unstructured":"Baumhakel M, Muller U, Bohm M (2009) Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. Eur J Heart Fail 11:299\u2013303. https:\/\/doi.org\/10.1093\/eurjhf\/hfn041","journal-title":"Eur J Heart Fail"},{"key":"2782_CR22","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1136\/hrt.2006.099523","volume":"94","author":"MJ Lenzen","year":"2008","unstructured":"Lenzen MJ, Rosengren A, Scholte op Reimer WJ et al (2008) Management of patients with heart failure in clinical practice: differences between men and women. Heart 94:e10. https:\/\/doi.org\/10.1136\/hrt.2006.099523","journal-title":"Heart"},{"key":"2782_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ehf2.12251","volume":"5","author":"H Norberg","year":"2018","unstructured":"Norberg H, Bergdahl E, Lindmark K (2018) Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study. ESC Heart Fail 5:337\u2013343. https:\/\/doi.org\/10.1002\/ehf2.12251","journal-title":"ESC Heart Fail"},{"key":"2782_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.phrs.2006.11.001","volume":"55","author":"F Franconi","year":"2007","unstructured":"Franconi F, Brunelleschi S, Steardo L, Cuomo V (2007) Gender differences in drug responses. Pharmacol Res 55:81\u201395. https:\/\/doi.org\/10.1016\/j.phrs.2006.11.001","journal-title":"Pharmacol Res"},{"key":"2782_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","volume":"48","author":"OP Soldin","year":"2009","unstructured":"Soldin OP, Mattison DR (2009) Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 48:143\u2013157. https:\/\/doi.org\/10.2165\/00003088-200948030-00001","journal-title":"Clin Pharmacokinet"},{"key":"2782_CR26","doi-asserted-by":"publisher","unstructured":"Jonsson A, Norberg H, Bergdahl E, Lindmark K (2018) Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population. Cardiovasc Ther:e12459. https:\/\/doi.org\/10.1111\/1755-5922.12459","DOI":"10.1111\/1755-5922.12459"},{"key":"2782_CR27","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","volume":"15","author":"AP Maggioni","year":"2013","unstructured":"Maggioni AP, Dahlstrom U, Filippatos G et al (2013) EURObservational research programme: regional differences and 1-year follow-up results of the heart failure pilot survey (ESC-HF Pilot). Eur J Heart Fail 15:808\u2013817. https:\/\/doi.org\/10.1093\/eurjhf\/hft050","journal-title":"Eur J Heart Fail"},{"key":"2782_CR28","doi-asserted-by":"publisher","unstructured":"Savarese G, Carrero JJ, Pitt B et al (2018) Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.1182","DOI":"10.1002\/ejhf.1182"},{"key":"2782_CR29","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/ejhf.788","volume":"19","author":"P Pellicori","year":"2017","unstructured":"Pellicori P, Urbinati A, Shah P, MacNamara A, Kazmi S, Dierckx R, Zhang J, Cleland JGF, Clark AL (2017) What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? Eur J Heart Fail 19:768\u2013778. https:\/\/doi.org\/10.1002\/ejhf.788","journal-title":"Eur J Heart Fail"},{"key":"2782_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.repc.2017.09.023","volume":"37","author":"G Rodrigues","year":"2018","unstructured":"Rodrigues G, Tralhao A, Aguiar C, Freitas P, Ventosa A, Mendes M (2018) Is the PARADIGM-HF cohort representative of the real-world heart failure patient population? Rev Port Cardiol 37:491\u2013496. https:\/\/doi.org\/10.1016\/j.repc.2017.09.023","journal-title":"Rev Port Cardiol"},{"key":"2782_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ijcard.2017.10.068","volume":"255","author":"A Aimo","year":"2018","unstructured":"Aimo A, Vergaro G, Barison A, Maffei S, Borrelli C, Morrone D, Cameli M, Palazzuoli A, Ambrosio G, Coiro S, Savino K, Cerbai E, Marcucci R, Pedrinelli R, Padeletti L, Passino C, Emdin M (2018) Sex-related differences in chronic heart failure. Int J Cardiol 255:145\u2013151. https:\/\/doi.org\/10.1016\/j.ijcard.2017.10.068","journal-title":"Int J Cardiol"},{"key":"2782_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jacc.2018.09.081","volume":"73","author":"P Dewan","year":"2019","unstructured":"Dewan P, Rorth R, Jhund PS et al (2019) Differential Impact of heart failure with reduced ejection fraction on men and women. J Am Coll Cardiol 73:29\u201340. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.081","journal-title":"J Am Coll Cardiol"},{"key":"2782_CR33","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ejhf.510","volume":"18","author":"M Komajda","year":"2016","unstructured":"Komajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, Tavazzi L, QUALIFY Investigators (2016) Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail 18:514\u2013522. https:\/\/doi.org\/10.1002\/ejhf.510","journal-title":"Eur J Heart Fail"},{"key":"2782_CR34","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.ejheart.2007.09.008","volume":"9","author":"P de Groote","year":"2007","unstructured":"de Groote P, Isnard R, Assyag P, Clerson P, Ducardonnet A, Galinier M, Jondeau G, Leurs I, Th\u00e9baut JF, Komajda M (2007) Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail 9:1205\u20131211. https:\/\/doi.org\/10.1016\/j.ejheart.2007.09.008","journal-title":"Eur J Heart Fail"},{"key":"2782_CR35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijcard.2017.01.018","volume":"232","author":"C Vitale","year":"2017","unstructured":"Vitale C, Fini M, Spoletini I, Lainscak M, Seferovic P, Rosano GM (2017) Under-representation of elderly and women in clinical trials. Int J Cardiol 232:216\u2013221. https:\/\/doi.org\/10.1016\/j.ijcard.2017.01.018","journal-title":"Int J Cardiol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02782-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02782-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02782-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:09:14Z","timestamp":1609546154000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02782-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["2782"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02782-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"23 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}